DiaMedica Reports Positive Phase 2 Data for DM199 in Preeclampsia, Advances Fetal Growth Restriction Trial — DiaMedica Therapeutics Inc.

Event summary

DM199 showed clinically meaningful reductions in blood pressure and uterine artery pulsatility index in preeclampsia patients during Phase 2 Part 1a study.
First cohort of fetal growth restriction trial completed enrollment, marking the first use of DM199 in early-onset fetal growth restriction patients.
ReMEDy2 Phase 2/3 stroke trial enrollment surpassed 85% of target participants, with interim analysis expected in early 2027.
Cash position decreased to $43.5M as of June 30, 2026, down from $59.9M at year-end 2025.

The big picture

DiaMedica's progress with DM199 in preeclampsia and fetal growth restriction positions it as a key player in addressing high-unmet medical needs in pregnancy-related ischemic diseases. The company's strategic focus on expanding clinical trials globally, particularly in the U.S., Canada, and Europe, aligns with broader industry trends toward decentralized trial designs to accelerate drug development.

What we're watching

Clinical Validation: Whether DM199's positive Phase 2 results in preeclampsia will translate to successful outcomes in larger, later-stage trials.
Regulatory Pathway: The pace at which DiaMedica can secure FDA clearance for its preeclampsia program following the ongoing rat pharmacokinetic study.
Financial Runway: How long DiaMedica's current cash position will sustain operations through 2027, given increasing R&D expenses.